Showing 5111-5120 of 5621 results for "".
- DORC Obtains 510k Clearance for Launch of EVA Upgrade Enhancementshttps://modernod.com/news/dorc-obtains-510k-clearance-for-launch-of-eva-upgrade-enhancements/2476922/DORC has announced 510(k) clearance for a range of enhancements to the EVA surgical system. The enhancements has been developed in close collaboration with surgeons and deliver both OR efficiency and surgical performa
- Eversight to Offer Preloaded DMEK in DORC Tubehttps://modernod.com/news/eversight-first-to-offer-preloaded-dmek-in-dorc-tube/2476911/Eversight announced it is the first eye bank to prepare preloaded Descemet membrane endothelial keratoplasty (DMEK) tissue in the Melles DORC tube, offering corneal surgeons more preloaded tissue options that further streamline surgeries and reduce cost, according to a company news release. <
- Novo Nordisk’s Rybelsus Gains FDA Approval as First Oral GLP-1 Receptor Agonist for Type 2 Diabeteshttps://modernod.com/news/novo-nordisks-rybelsus-gains-fda-approval-as-first-oral-glp-1-receptor-agonist-for-type-2-diabetes/2476907/The FDA announced Friday the approval of Novo Nordisk’s Rybelsus (semaglutide) to improve control of blood glucose in adults with type 2 diabetes, along with diet and exercise, making it the first oral GLP-1 receptor agonist cleared in the US. Lisa Yanoff, acting director of the Division of
- Sifi Appoints New Country Manager for Italyhttps://modernod.com/news/sifi-appoints-new-country-manager-for-italy/2476904/Sifi has announced that Fabrizio Folco has joined the company as “Country Manager Italy,” and will be responsible for accelerating company development on the Italian market through management of the company’s commercial strategy and organization, for both pharma and surgical are
- US House Speaker Nancy Pelosi Introduces Plan to Permit Price Negotiation for Some Drugshttps://modernod.com/news/us-house-speaker-nancy-pelosi-introduces-plan-to-permit-price-negotiation-for-some-drugs/2476901/US House Speaker Nancy Pelosi on Thursday unveiled proposed legislation that would permit the federal government to negotiate prices of drugs for Medicare and other health programs. Specifically, the proposal would empower the Department of Health and Human Services (HHS) to annually ne
- Konan Medical’s EyeKinetix Pupillograph is Now Available in the United Stateshttps://modernod.com/news/konan-medicals-eyekinetix-pupillograph-is-now-available-in-the-united-states/2476902/Konan Medical announced that EyeKinetix is FDA listed and now available for sale in the United States. EyeKinetix is Konan’s 2nd generation pupillograph, which is smaller, faster, easier to use and less expensive than its predecessor, RAPDx, a device that brought key pupillary testin
- Eye Cancer Researchers at Bascom Palmer and Sylvester Identify Function of Key Tumor Suppressorhttps://modernod.com/news/eye-cancer-researchers-at-bascom-palmer-and-sylvester-identify-function-of-key-tumor-suppressor/2476900/Cancer cells remember things they shouldn’t. During development, stem and progenitor cells move freely through the body as they differentiate into heart, brain, liver, and eyes. But after humans are born, that process should stop. Cells shouldn’t travel or change anymore; they should stay put and
- Graybug Vision Initiates Clinical Trial in Macular Edema Secondary to DME or RVOhttps://modernod.com/news/graybug-vision-initiates-clinical-trial-in-macular-edema-secondary-to-dme-or-rvo/2476898/Graybug Vision announced the initiation of its phase 2a study with GB-102 in patients with macular edema (ME) secondary to diabetic macular edema (DME) or retinal vein occlusion (RVO). GB-102, a pan-Vascular Endothelial Growth Factor (VEGF) inhibitor and potential twice-per-year therapy is
- Oyster Point Pharma Expands Executive Leadership Teamhttps://modernod.com/news/oyster-point-pharma-expands-executive-leadership-team/2476896/Oyster Point Pharma announced the appointment of Dan Lochner, MBA, as its Chief Financial Officer, and John Snisarenko, MBA, as Chief Commercial Officer. Mr. Lochner joins Oyster Point Pharma after spending nearly 15 years, most recently as a Managing Director, at Goldman Sachs asset mana
- Phase 2 Study Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to AMDhttps://modernod.com/news/phase-2-study-highlights-efficacy-and-safety-data-of-intravitreal-apl-2-for-geographic-atrophy-secondary-to-amd/2476891/Apellis Pharmaceuticals announced details about its phase 2 FILLY study investigating intravitreal (IVT) APL-2 (pegcetacoplan) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) have been published in Ophth